Clinical trial Recruiting at 1 site Phase2; Phase3 Interventional Ages 18 and up

Ozone therapy for numbness and tingling from chemotherapy

Official title: Effectiveness and Cost-effectiveness of Ozone Treatment in Patients With Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (OzoParQT)

Run by Hospital Universitario de Gran Canaria Doctor Negrín · NCT06706544 · Data updated 2026-11-12

This study is testing if ozone therapy can help reduce numbness and tingling in cancer patients who have nerve damage from chemotherapy.

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment42 (estimated)
SponsorHospital Universitario de Gran Canaria Doctor Negrín
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Las Palmas, Las Palmas)
StatusRecruiting
StartedFebruary 7, 2025
Main results expectedDecember 31, 2029
Study endsMarch 31, 2030
Registry record updatedSeptember 18, 2026
Trial IDNCT06706544 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 years old who have experienced moderate to severe paresthesia due to chemotherapy for at least three months.

Probably not a fit

Patients who are under 18, pregnant, or have active neurotoxic chemotherapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of rectal ozone therapy in improving symptoms of numbness and tingling caused by chemotherapy-induced peripheral neuropathy (CIPN). It involves a randomized comparison between ozone and placebo (oxygen) treatments over 16 weeks, with a focus on patients' self-perceived levels of paresthesia and health-related quality of life. The study aims to provide insights into the potential benefits of ozone therapy as an adjunct treatment for CIPN, which currently has limited therapeutic options.

Why it matters

Potential benefit: If successful, this treatment could significantly alleviate symptoms of numbness and tingling in patients suffering from CIPN, enhancing their quality of life.

How similar studies have gone: While ozone therapy is a novel approach in this context, previous studies have suggested potential benefits, though this specific application remains largely untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 1\. Adults \> = 18 years old.
* 2\. Previous treatment with any chemotherapy because of any tumor.
* 3\. Clinical diagnosis of paresthesia (numbness, tingling) secondary to CIPN, with toxicity Grade \> = 2 (according to the Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute of EEUU, v.5.0) for \> = 3 months.
* 4\. Without neurotoxic chemotherapy \> = 3 months.
* 5\. Cancer disease is stable or in remission.
* 6\. Life expectancy \> = 6 months.
* 7\. Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit and accept the use of appropriate contraceptive methods at least from 14 days before the first ozone therapy session up to 14 days after the last one.
* 8\. To sign and date the study-specific informed consent

Exclusion Criteria:

* 1\. Age \< 18 years.
* 2\. A woman who is lactating, pregnant, suspected of being pregnant, or a woman of childbearing potential who does not use adequate contraceptive methods.
* 3\. Suspected symptoms are due to diabetic or compressive neuropathy.
* 4\. Severe psychiatric disorders.
* 5\. Inability to complete the quality of life questionnaires.
* 6\. Elevation above 5 times the maximum limit of normal creatinine.
* 7\. Patient who is hemodynamic or clinically unstable or who requires urgent or short-term interventional measures.
* 8\. Neoplasia in progression requiring recent initiation of systemic treatment or maintenance with neurotoxic chemotherapy.
* 9\. Life expectancy (for any reason) \< 6 months.
* 10\. Known allergy to ozone, known glucose 6 phosphate dehydrogenase (G6PD) deficiency, or hemochromatosis.
* 11\. Contraindications or impossibility for rectal ozone treatment or to attend regularly to the treatment.
* 12\. Not meeting each and every one of the inclusion criteria

Where it's running

  • Dr. Negrín University Hospital
    Las Palmas, Las Palmas, Spain
    Recruiting

Study contacts

  • Principal investigator: Himar Fabelo, BSc, PhD — Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
  • Study coordinator: Bernardino Clavo, MD, PhD
  • Email: bernardinoclavo@gmail.com
  • Phone: 34928449278

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.